Workflow
Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings
Bio-TechneBio-Techne(US:TECH) ZACKSยท2025-08-06 14:31

Core Insights - Techne (TECH) reported revenue of $316.96 million for the quarter ended June 2025, marking a year-over-year increase of 3.6% and exceeding the Zacks Consensus Estimate of $315.44 million by 0.48% [1] - The company achieved an EPS of $0.53, up from $0.49 a year ago, with a surprise of 6% compared to the consensus estimate of $0.50 [1] Financial Performance Metrics - Organic Growth for the company was reported at 3%, aligning with the three-analyst average estimate of 3% [4] - Organic Growth in Diagnostics and Spatial Biology was -1%, falling short of the estimated 2.3% by two analysts [4] - Organic Growth in Protein Sciences was 4%, surpassing the two-analyst average estimate of 2.7% [4] - Net Sales from intersegment revenue was $0.79 million, significantly better than the average estimate of -$0.5 million, representing a year-over-year change of -225.3% [4] - Net Sales in Protein Sciences reached $226.47 million, exceeding the two-analyst average estimate of $224.65 million, with a year-over-year increase of 5.8% [4] - Net Sales in Diagnostics and Spatial Biology were $89.71 million, below the estimated $92.75 million, reflecting a -1.1% change compared to the previous year [4] Stock Performance - Techne's shares have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]